These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 20716232)

  • 1. Drugs, money and society (Part II).
    Walley T
    Br J Clin Pharmacol; 2010 Sep; 70(3):342-5. PubMed ID: 20716232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacoeconomics: NICE's approach to decision-making.
    Rawlins M; Barnett D; Stevens A
    Br J Clin Pharmacol; 2010 Sep; 70(3):346-9. PubMed ID: 20716233
    [No Abstract]   [Full Text] [Related]  

  • 3. From NCE to NICE: the role of pharmacoeconomics.
    Hughes DA
    Br J Clin Pharmacol; 2010 Sep; 70(3):317-9. PubMed ID: 20716229
    [No Abstract]   [Full Text] [Related]  

  • 4. Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong?
    Towse A
    Br J Clin Pharmacol; 2010 Sep; 70(3):360-6. PubMed ID: 20716236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In that case: a pharmaceutical company that makes generic versions of commonly used drugs has produced a generic of a proprietary drug widely prescribed in a particular service. Response.
    Adams J
    N Z Bioeth J; 2003 Oct; 4(3):22-3. PubMed ID: 15597478
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmaceutical economy and the economic assessment of drugs in France.
    le Pen C
    Soc Sci Med; 1997 Aug; 45(4):635-43. PubMed ID: 9226787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacoeconomics is coming of age.
    Pizzi L; Singh V
    Clin Pharmacol Ther; 2008 Aug; 84(2):188-90. PubMed ID: 18679179
    [No Abstract]   [Full Text] [Related]  

  • 8. Spending on pharmaceuticals in Italy: macro constraints with local autonomy.
    Mapelli V; Lucioni C
    Value Health; 2003; 6 Suppl 1():S31-45. PubMed ID: 12846924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Public drug expenditure in the Republic of Ireland.
    Barry M; Usher C; Tilson L
    Expert Rev Pharmacoecon Outcomes Res; 2010 Jun; 10(3):239-45. PubMed ID: 20545588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementing pharmacoeconomic guidelines in Latin America: lessons learned.
    Augustovski F; Melendez G; Lemgruber A; Drummond M
    Value Health; 2011; 14(5 Suppl 1):S3-7. PubMed ID: 21839895
    [No Abstract]   [Full Text] [Related]  

  • 11. In that case: a pharmaceutical company that makes generic versions of commonly used drugs has produced a generic of a proprietary drug widely prescribed in a particular service. Response.
    Menkes DB; Woodall AA
    N Z Bioeth J; 2003 Oct; 4(3):22, 24-5. PubMed ID: 15597480
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacoeconomics: basic concepts and terminology.
    Walley T; Haycox A
    Br J Clin Pharmacol; 1997 Apr; 43(4):343-8. PubMed ID: 9146844
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug Policy in Estonia.
    Mägi K; Lepaste M; Szkultecka-Dębek M
    Value Health Reg Issues; 2018 Sep; 16():1-4. PubMed ID: 29529444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Separate pharmaceutical budgets: skating on thin ice].
    Egberts AC; de Boer A
    Ned Tijdschr Geneeskd; 2010; 154(51-52):A3004. PubMed ID: 21211087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The context for health reform in the United Kingdom, Sweden, Germany, and the United States.
    Saltman RB
    Health Policy; 1997 Sep; 41 Suppl():S9-26. PubMed ID: 10174476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges to achieving value in drug spending in a decentralized country: the Spanish case.
    Antoñanzas F
    Value Health; 2003; 6 Suppl 1():S52-63. PubMed ID: 12846926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Application of pharmacoeconomics in clinical management].
    Amat Díaz M; Poveda Andrés JL; Carrera-Hueso FJ
    Farm Hosp; 2011 May; 35 Suppl 2():18-24. PubMed ID: 22445505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug Policy in Latvia.
    Silins J; Szkultecka-Dębek M
    Value Health Reg Issues; 2017 Sep; 13():73-78. PubMed ID: 29073995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [May drugs be a cost-effective investment in Spanish health system?].
    Soto J; Olivella P
    Med Clin (Barc); 2001 Nov; 117(16):622-4. PubMed ID: 11714470
    [No Abstract]   [Full Text] [Related]  

  • 20. The impact of pharmaceutical marketing on market access, treatment coverage, pricing, and social welfare.
    Critchley GJ; Zaric GS
    Health Econ; 2019 Aug; 28(8):1035-1051. PubMed ID: 31310424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.